CLDN14

Across TCGA pan-cancer cohorts, CLDN14 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated CLDN14 data layer compared with 2 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher CLDN14 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CLDN14 expression acts as an unfavorable survival marker, although some lineages such as LIHC and HNSC show a favorable association.

MESO, KIRC, and LIHC are the cancer types where CLDN14 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	All	0.262	0.591	<.001	90	view →
KIRC	DFS	Tertile	All	0.519	0.798	<.001	46	view →
LIHC	OS	Quartile	All	0.720	0.429	<.001	43	view →
THCA	DFS	Median	All	0.769	0.887	.003	41	view →
LGG	DFS	Median	All	0.628	0.804	<.001	33	view →
SCLC	DFS	Quartile	III,IV	0.250	0.619	.002	32	view →
LUAD	DFS	Quartile	All	0.699	0.840	.002	22	view →
CHOL	DFS	Median	III,IV	0.127	0.647	.006	19	view →
HNSC	DFS	Tertile	IV	0.527	0.358	.011	19	view →
LUSC	OS	Tertile	All	0.337	0.476	.021	19	view →
STAD	DFS	Tertile	II,III,IV	0.250	0.543	.010	18	view →
GBM	OS	Quartile	All	0.330	0.502	.009	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

CLDN14–MESO (OS)

Open the MESO breakdown →